

## Special Issue

# Immune Response and Antigen-Specific Personalized Therapeutics in Multiple Sclerosis-the Upcoming Era of Precision Medicine

### Message from the Guest Editors

*Multiple sclerosis (MS)* is an autoimmune disorder characterized by T cell-mediated demyelination and neurodegeneration of the central nervous system (CNS), whose exact etiology remains unclear. The autoimmune view of MS is strongly supported by the use of the animal *experimental autoimmune encephalomyelitis (EAE)* model, which displays some of the key MS characteristics. During the effector phase, CD4+ T cells that recognize antigen proliferate, cross the *blood-brain barrier (BBB)* and subsequently activate macrophages and *microglia* that cause demyelination, oligodendrocyte death, and axon degeneration. As the disease progresses, remyelination and regeneration of oligodendrocyte become inefficient and ultimately fail, resulting in disease progression. This Special Issue aims at gathering articles *on immune response toward personalized therapeutics in MS*, through the contribution of MS specialists around the world, taking into account the progress in the field in the last two decades.

### Guest Editors

Dr. Maria Anagnostouli

Director of Multiple Sclerosis & Demyelinating Diseases Unit and Immunogenetics Laboratory, 1st Department of Neurology of Medical School, National and Kapodistrian University of Athens, Aeginition University Hospital, Vas. Sofias Ave 74, 115 28 Athens, Greece

Prof. Dr. George P. Chrousos

University Research Institute of Maternal and Child Health and Precision Medicine, Medical School, "Aghia Sophia" Children's Hospital, National and Kapodistrian University of Athens, 15772 Athens, Greece

### Deadline for manuscript submissions

closed (20 June 2021)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/64847](https://mdpi.com/si/64847)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).